WO2021256861A1 - 신규한 산 분비 억제제 및 이의 용도 - Google Patents
신규한 산 분비 억제제 및 이의 용도 Download PDFInfo
- Publication number
- WO2021256861A1 WO2021256861A1 PCT/KR2021/007572 KR2021007572W WO2021256861A1 WO 2021256861 A1 WO2021256861 A1 WO 2021256861A1 KR 2021007572 W KR2021007572 W KR 2021007572W WO 2021256861 A1 WO2021256861 A1 WO 2021256861A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- ulcer
- methoxy
- gastric
- pharmaceutically acceptable
- Prior art date
Links
- 230000009858 acid secretion Effects 0.000 title abstract description 15
- 239000003112 inhibitor Substances 0.000 title description 12
- 150000001875 compounds Chemical class 0.000 claims abstract description 166
- 150000003839 salts Chemical class 0.000 claims abstract description 68
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 55
- 238000000034 method Methods 0.000 claims description 42
- 230000002496 gastric effect Effects 0.000 claims description 40
- -1 methoxy, ethoxy, methyl Chemical group 0.000 claims description 40
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 33
- 210000004211 gastric acid Anatomy 0.000 claims description 33
- 201000010099 disease Diseases 0.000 claims description 32
- 208000017189 Gastrointestinal inflammatory disease Diseases 0.000 claims description 29
- 239000003814 drug Substances 0.000 claims description 26
- 206010061459 Gastrointestinal ulcer Diseases 0.000 claims description 24
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 22
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 19
- 241000590002 Helicobacter pylori Species 0.000 claims description 16
- 229940037467 helicobacter pylori Drugs 0.000 claims description 16
- 208000000718 duodenal ulcer Diseases 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 13
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 13
- 206010063655 Erosive oesophagitis Diseases 0.000 claims description 12
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 12
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 12
- 208000025865 Ulcer Diseases 0.000 claims description 11
- 201000005917 gastric ulcer Diseases 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 208000007882 Gastritis Diseases 0.000 claims description 10
- 208000008469 Peptic Ulcer Diseases 0.000 claims description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 9
- 206010017758 gastric cancer Diseases 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- 201000011549 stomach cancer Diseases 0.000 claims description 9
- 231100000397 ulcer Toxicity 0.000 claims description 9
- 201000006549 dyspepsia Diseases 0.000 claims description 8
- 208000000689 peptic esophagitis Diseases 0.000 claims description 8
- 208000011906 peptic ulcer disease Diseases 0.000 claims description 8
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 claims description 7
- 206010020601 Hyperchlorhydria Diseases 0.000 claims description 6
- 206010042220 Stress ulcer Diseases 0.000 claims description 6
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 claims description 6
- 230000037328 acute stress Effects 0.000 claims description 6
- 208000017215 gastric mucosa-associated lymphoid tissue lymphoma Diseases 0.000 claims description 6
- 201000000052 gastrinoma Diseases 0.000 claims description 6
- 230000035882 stress Effects 0.000 claims description 6
- 206010019375 Helicobacter infections Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- HBTFAOVKDHXLED-UHFFFAOYSA-N 1-[5-(2,4-difluorophenyl)-4-methoxy-1-(6-methylpyridin-3-yl)sulfonylpyrrol-3-yl]-N-methylmethanamine Chemical compound CC(N=C1)=CC=C1S(N(C=C1CNC)C(C(C=CC(F)=C2)=C2F)=C1OC)(=O)=O HBTFAOVKDHXLED-UHFFFAOYSA-N 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- KRUVIMJPCGDIQU-UHFFFAOYSA-N 1-[5-(2,4-difluorophenyl)-4-methoxy-1-(6-methoxypyridin-3-yl)sulfonylpyrrol-3-yl]-N-methylmethanamine Chemical compound CNCC(C(OC)=C1C(C=CC(F)=C2)=C2F)=CN1S(C(C=N1)=CC=C1OC)(=O)=O KRUVIMJPCGDIQU-UHFFFAOYSA-N 0.000 claims description 3
- WEDFJKVJJPHJPU-UHFFFAOYSA-N 1-[5-(2-fluorophenyl)-4-methoxy-1-(6-methylpyridin-3-yl)sulfonylpyrrol-3-yl]-N-methylmethanamine Chemical compound CC(N=C1)=CC=C1S(N(C=C1CNC)C(C(C=CC=C2)=C2F)=C1OC)(=O)=O WEDFJKVJJPHJPU-UHFFFAOYSA-N 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 29
- 239000000126 substance Substances 0.000 abstract description 3
- 238000006243 chemical reaction Methods 0.000 description 112
- 239000000543 intermediate Substances 0.000 description 66
- 239000000243 solution Substances 0.000 description 66
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 58
- 238000003786 synthesis reaction Methods 0.000 description 53
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 48
- 230000000694 effects Effects 0.000 description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 34
- 210000002784 stomach Anatomy 0.000 description 34
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 32
- 239000012044 organic layer Substances 0.000 description 29
- 238000012360 testing method Methods 0.000 description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- 230000015572 biosynthetic process Effects 0.000 description 26
- 230000006378 damage Effects 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 239000007787 solid Substances 0.000 description 23
- 229940079593 drug Drugs 0.000 description 22
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- 238000004440 column chromatography Methods 0.000 description 21
- 229920000609 methyl cellulose Polymers 0.000 description 20
- 239000001923 methylcellulose Substances 0.000 description 20
- 235000010981 methylcellulose Nutrition 0.000 description 20
- 230000027119 gastric acid secretion Effects 0.000 description 19
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 102400000921 Gastrin Human genes 0.000 description 17
- 108010052343 Gastrins Proteins 0.000 description 17
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 17
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 17
- 238000003756 stirring Methods 0.000 description 17
- 238000005481 NMR spectroscopy Methods 0.000 description 16
- 241000700159 Rattus Species 0.000 description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- 102100032709 Potassium-transporting ATPase alpha chain 2 Human genes 0.000 description 15
- 108010083204 Proton Pumps Proteins 0.000 description 15
- 230000028327 secretion Effects 0.000 description 15
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 14
- 206010060377 Hypergastrinaemia Diseases 0.000 description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 229940126409 proton pump inhibitor Drugs 0.000 description 13
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 239000012267 brine Substances 0.000 description 11
- 238000000605 extraction Methods 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 210000000813 small intestine Anatomy 0.000 description 11
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 229940126535 potassium competitive acid blocker Drugs 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 102000005157 Somatostatin Human genes 0.000 description 8
- 108010056088 Somatostatin Proteins 0.000 description 8
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 8
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 8
- 201000011519 neuroendocrine tumor Diseases 0.000 description 8
- ROSDSFDQCJNGOL-UHFFFAOYSA-N protonated dimethyl amine Natural products CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 230000035484 reaction time Effects 0.000 description 8
- 229910000104 sodium hydride Inorganic materials 0.000 description 8
- 229960000553 somatostatin Drugs 0.000 description 8
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 7
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 210000001198 duodenum Anatomy 0.000 description 7
- 210000004051 gastric juice Anatomy 0.000 description 7
- 229910052736 halogen Inorganic materials 0.000 description 7
- 150000002367 halogens Chemical class 0.000 description 7
- 229960000905 indomethacin Drugs 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 239000012046 mixed solvent Substances 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 7
- 125000004076 pyridyl group Chemical group 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- CHNYVNOFAWYUEG-UHFFFAOYSA-N 1h-pyrrole-3-carbaldehyde Chemical compound O=CC=1C=CNC=1 CHNYVNOFAWYUEG-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 230000001747 exhibiting effect Effects 0.000 description 6
- 210000001156 gastric mucosa Anatomy 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 206010020718 hyperplasia Diseases 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- DOYOPBSXEIZLRE-UHFFFAOYSA-N pyrrole-3-carboxylic acid Chemical compound OC(=O)C=1C=CNC=1 DOYOPBSXEIZLRE-UHFFFAOYSA-N 0.000 description 6
- 238000013222 sprague-dawley male rat Methods 0.000 description 6
- 239000006188 syrup Substances 0.000 description 6
- 235000020357 syrup Nutrition 0.000 description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 5
- 229940123051 Somatostatin receptor agonist Drugs 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 239000003638 chemical reducing agent Substances 0.000 description 5
- 210000004188 enterochromaffin-like cell Anatomy 0.000 description 5
- 150000002170 ethers Chemical class 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 210000001711 oxyntic cell Anatomy 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 208000010643 digestive system disease Diseases 0.000 description 4
- 210000003238 esophagus Anatomy 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- DMNUDNHYRCDZDC-UHFFFAOYSA-N methyl 5-(2,4-difluorophenyl)-4-methoxy-1H-pyrrole-3-carboxylate Chemical compound COC(=O)C1=CNC(=C1OC)C1=C(F)C=C(F)C=C1 DMNUDNHYRCDZDC-UHFFFAOYSA-N 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- BGCSUJHSGHKXKF-UHFFFAOYSA-N pyrrole-1,3-dicarboxylic acid Chemical compound OC(=O)C=1C=CN(C(O)=O)C=1 BGCSUJHSGHKXKF-UHFFFAOYSA-N 0.000 description 4
- FDDQRDMHICUGQC-UHFFFAOYSA-M pyrrole-1-carboxylate Chemical compound [O-]C(=O)N1C=CC=C1 FDDQRDMHICUGQC-UHFFFAOYSA-M 0.000 description 4
- 238000011552 rat model Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 108010064556 somatostatin receptor subtype-4 Proteins 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- 229950003825 vonoprazan Drugs 0.000 description 4
- BFDBKMOZYNOTPK-UHFFFAOYSA-N vonoprazan Chemical compound C=1C=CN=CC=1S(=O)(=O)N1C=C(CNC)C=C1C1=CC=CC=C1F BFDBKMOZYNOTPK-UHFFFAOYSA-N 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 3
- VOHGUSRHQKRYCA-UHFFFAOYSA-N 1-O-tert-butyl 3-O-methyl 5-(2-fluorophenyl)-4-methoxypyrrole-1,3-dicarboxylate Chemical compound CC(C)(C)OC(N(C=C1C(OC)=O)C(C(C=CC=C2)=C2F)=C1OC)=O VOHGUSRHQKRYCA-UHFFFAOYSA-N 0.000 description 3
- VFTFKUDGYRBSAL-UHFFFAOYSA-N 15-crown-5 Chemical compound C1COCCOCCOCCOCCO1 VFTFKUDGYRBSAL-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- RBSUVNKSTRDWQE-UHFFFAOYSA-N COC(=O)C1=CN(C(=O)OC(C)(C)C)C(=C1OC)C1=C(F)C=C(F)C=C1 Chemical compound COC(=O)C1=CN(C(=O)OC(C)(C)C)C(=C1OC)C1=C(F)C=C(F)C=C1 RBSUVNKSTRDWQE-UHFFFAOYSA-N 0.000 description 3
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 3
- 206010013710 Drug interaction Diseases 0.000 description 3
- RHAXSHUQNIEUEY-UHFFFAOYSA-N Epirizole Chemical compound COC1=CC(C)=NN1C1=NC(C)=CC(OC)=N1 RHAXSHUQNIEUEY-UHFFFAOYSA-N 0.000 description 3
- 206010061172 Gastrointestinal injury Diseases 0.000 description 3
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108010016076 Octreotide Proteins 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 108050001286 Somatostatin Receptor Proteins 0.000 description 3
- 102000011096 Somatostatin receptor Human genes 0.000 description 3
- 102100023801 Somatostatin receptor type 4 Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 208000023652 chronic gastritis Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 3
- 230000002183 duodenal effect Effects 0.000 description 3
- 229950003801 epirizole Drugs 0.000 description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000008297 liquid dosage form Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- IOQOMRHBWGQFMR-UHFFFAOYSA-N methyl 5-(2-fluorophenyl)-4-methoxy-1H-pyrrole-3-carboxylate Chemical compound FC1=C(C=CC=C1)C1=C(C(=CN1)C(=O)OC)OC IOQOMRHBWGQFMR-UHFFFAOYSA-N 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000007363 ring formation reaction Methods 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 238000012453 sprague-dawley rat model Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- NOIQQVJKCLXNAS-UHFFFAOYSA-N tert-butyl N-[[5-(2-fluorophenyl)-4-methoxy-1H-pyrrol-3-yl]methyl]-N-methylcarbamate Chemical compound CC(C)(C)OC(N(C)CC1=CNC(C(C=CC=C2)=C2F)=C1OC)=O NOIQQVJKCLXNAS-UHFFFAOYSA-N 0.000 description 3
- SZLUKAPNRMXZNZ-UHFFFAOYSA-N 1-O-tert-butyl 3-O-methyl 5-(2-fluorophenyl)-4-hydroxypyrrole-1,3-dicarboxylate Chemical compound CC(C)(C)OC(N(C=C1C(OC)=O)C(C(C=CC=C2)=C2F)=C1O)=O SZLUKAPNRMXZNZ-UHFFFAOYSA-N 0.000 description 2
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 2
- CVINMJDGSGBHTL-UHFFFAOYSA-N 2-(2,4-difluorophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NC(C(O)=O)C1=CC=C(F)C=C1F CVINMJDGSGBHTL-UHFFFAOYSA-N 0.000 description 2
- IUFATHQIUYUCFE-UHFFFAOYSA-N 2-(2-fluorophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NC(C(O)=O)C1=CC=CC=C1F IUFATHQIUYUCFE-UHFFFAOYSA-N 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 2
- PASGVETWJJIACY-UHFFFAOYSA-N 5-(2,4-difluorophenyl)-4-methoxy-1H-pyrrole-3-carbaldehyde Chemical compound COC1=C(C(C=CC(F)=C2)=C2F)NC=C1C=O PASGVETWJJIACY-UHFFFAOYSA-N 0.000 description 2
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 2
- OMLIVJOTRYWHNY-UHFFFAOYSA-N 6-methoxypyridine-3-sulfonyl chloride Chemical compound COC1=CC=C(S(Cl)(=O)=O)C=N1 OMLIVJOTRYWHNY-UHFFFAOYSA-N 0.000 description 2
- TWKVSHBWJUMVDX-UHFFFAOYSA-N 6-methylpyridine-3-sulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=N1 TWKVSHBWJUMVDX-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- BMWNLHUENBTDLY-UHFFFAOYSA-N COC(C(C=O)=C1)=C(C(C=CC(F)=C2)=C2F)N1S(C(C=N1)=CC=C1OC)(=O)=O Chemical compound COC(C(C=O)=C1)=C(C(C=CC(F)=C2)=C2F)N1S(C(C=N1)=CC=C1OC)(=O)=O BMWNLHUENBTDLY-UHFFFAOYSA-N 0.000 description 2
- SCLCQRZVJOCUEP-UHFFFAOYSA-N COC1=C(C(C=CC=C2)=C2F)NC=C1C=O Chemical compound COC1=C(C(C=CC=C2)=C2F)NC=C1C=O SCLCQRZVJOCUEP-UHFFFAOYSA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 239000001116 FEMA 4028 Substances 0.000 description 2
- 210000000712 G cell Anatomy 0.000 description 2
- 206010064147 Gastrointestinal inflammation Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 208000007920 Neurogenic Inflammation Diseases 0.000 description 2
- 206010058522 Oesophageal injury Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- TUDWJGFKGMQKGD-UHFFFAOYSA-N [5-(2,4-difluorophenyl)-4-methoxy-1-(6-methoxypyridin-3-yl)sulfonylpyrrol-3-yl]methanol Chemical compound COC(C(CO)=C1)=C(C(C=CC(F)=C2)=C2F)N1S(C(C=N1)=CC=C1OC)(=O)=O TUDWJGFKGMQKGD-UHFFFAOYSA-N 0.000 description 2
- HEEOTKDNLBXVAE-UHFFFAOYSA-N [5-(2,4-difluorophenyl)-4-methoxy-1-(6-methylpyridin-3-yl)sulfonylpyrrol-3-yl]methanol Chemical compound CC(N=C1)=CC=C1S(N(C=C1CO)C(C(C=CC(F)=C2)=C2F)=C1OC)(=O)=O HEEOTKDNLBXVAE-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 2
- 229960004853 betadex Drugs 0.000 description 2
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 150000003983 crown ethers Chemical class 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 230000008406 drug-drug interaction Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000008713 feedback mechanism Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 201000007028 gastrointestinal neuroendocrine tumor Diseases 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 208000028774 intestinal disease Diseases 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 230000000622 irritating effect Effects 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 108010021336 lanreotide Proteins 0.000 description 2
- 229960003174 lansoprazole Drugs 0.000 description 2
- SIXIIKVOZAGHPV-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=C[CH]C2=N1 SIXIIKVOZAGHPV-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- MSUKFLZKGPWROK-UHFFFAOYSA-N methyl 4-(2,4-difluorophenyl)-4-[(2-methylpropan-2-yl)oxycarbonylamino]-3-oxobutanoate Chemical compound C1(F)=CC(F)=C(C(C(=O)CC(=O)OC)NC(=O)OC(C)(C)C)C=C1 MSUKFLZKGPWROK-UHFFFAOYSA-N 0.000 description 2
- NANFGRFIIWDJCB-UHFFFAOYSA-N methyl 4-(2-fluorophenyl)-4-[(2-methylpropan-2-yl)oxycarbonylamino]-3-oxobutanoate Chemical compound CC(C)(C)OC(NC(C(CC(OC)=O)=O)C(C=CC=C1)=C1F)=O NANFGRFIIWDJCB-UHFFFAOYSA-N 0.000 description 2
- BTBXETDBJWOVBB-UHFFFAOYSA-N methyl 5-(2,4-difluorophenyl)-4-methoxy-1-(6-methylpyridin-3-yl)sulfonylpyrrole-3-carboxylate Chemical compound CC(N=C1)=CC=C1S(N(C=C1C(OC)=O)C(C(C=CC(F)=C2)=C2F)=C1OC)(=O)=O BTBXETDBJWOVBB-UHFFFAOYSA-N 0.000 description 2
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 2
- 230000006676 mitochondrial damage Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229960000381 omeprazole Drugs 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000006920 protein precipitation Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 230000020341 sensory perception of pain Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 229940075620 somatostatin analogue Drugs 0.000 description 2
- 210000002325 somatostatin-secreting cell Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- QRTLLQMKGWKRTN-UHFFFAOYSA-N tert-butyl 2-(2,4-difluorophenyl)-4-(hydroxymethyl)-3-methoxypyrrole-1-carboxylate Chemical compound CC(C)(C)OC(N(C=C1CO)C(C(C=CC(F)=C2)=C2F)=C1OC)=O QRTLLQMKGWKRTN-UHFFFAOYSA-N 0.000 description 2
- UEKUJEAHKDOACM-UHFFFAOYSA-N tert-butyl 2-(2,4-difluorophenyl)-4-formyl-3-methoxypyrrole-1-carboxylate Chemical compound CC(C)(C)OC(N(C=C1C=O)C(C(C=CC(F)=C2)=C2F)=C1OC)=O UEKUJEAHKDOACM-UHFFFAOYSA-N 0.000 description 2
- RPUXMZQVHILKLZ-UHFFFAOYSA-N tert-butyl 2-(2-fluorophenyl)-4-(hydroxymethyl)-3-methoxypyrrole-1-carboxylate Chemical compound CC(C)(C)OC(N(C=C1CO)C(C(C=CC=C2)=C2F)=C1OC)=O RPUXMZQVHILKLZ-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- QDRCKDBKMASOFW-UHFFFAOYSA-N 1-O-tert-butyl 3-O-methyl 5-(2,4-difluorophenyl)-4-hydroxypyrrole-1,3-dicarboxylate Chemical compound C1(F)=CC(=C(C2=C(O)C(C(=O)OC)=CN2C(=O)OC(C)(C)C)C=C1)F QDRCKDBKMASOFW-UHFFFAOYSA-N 0.000 description 1
- UDMABANYJMEZDH-UHFFFAOYSA-N 1-[5-(2-fluorophenyl)-4-methoxy-1-(6-methoxypyridin-3-yl)sulfonylpyrrol-3-yl]-N-methylmethanamine Chemical compound CNCC(C(OC)=C1C(C=CC=C2)=C2F)=CN1S(C(C=N1)=CC=C1OC)(=O)=O UDMABANYJMEZDH-UHFFFAOYSA-N 0.000 description 1
- KADJPCISBMHDBP-UHFFFAOYSA-N 1-[5-(2-fluorophenyl)-4-methoxy-1-pyridin-2-ylsulfonylpyrrol-3-yl]-N-methylmethanamine Chemical compound CNCC(C(OC)=C1C(C=CC=C2)=C2F)=CN1S(C1=NC=CC=C1)(=O)=O KADJPCISBMHDBP-UHFFFAOYSA-N 0.000 description 1
- GPWNWKWQOLEVEQ-UHFFFAOYSA-N 2,4-diaminopyrimidine-5-carbaldehyde Chemical compound NC1=NC=C(C=O)C(N)=N1 GPWNWKWQOLEVEQ-UHFFFAOYSA-N 0.000 description 1
- COIWYFIMAXMSKX-UHFFFAOYSA-N 2-azaniumyl-2-(2,4-difluorophenyl)acetate Chemical compound OC(=O)C(N)C1=CC=C(F)C=C1F COIWYFIMAXMSKX-UHFFFAOYSA-N 0.000 description 1
- CGNMJIBUVDGMIY-UHFFFAOYSA-N 2-azaniumyl-2-(2-fluorophenyl)acetate Chemical compound OC(=O)C(N)C1=CC=CC=C1F CGNMJIBUVDGMIY-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- JCYPECIVGRXBMO-UHFFFAOYSA-N 4-(dimethylamino)azobenzene Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=CC=C1 JCYPECIVGRXBMO-UHFFFAOYSA-N 0.000 description 1
- YUWSYDYNEKIQLL-UHFFFAOYSA-N 6-methylpyridine-2-sulfonyl chloride Chemical compound CC1=CC=CC(S(Cl)(=O)=O)=N1 YUWSYDYNEKIQLL-UHFFFAOYSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 101100325788 Arabidopsis thaliana BCA1 gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- CYAXCSFTHFUALI-UHFFFAOYSA-N C(CC(=O)O)(=O)O.C[K] Chemical compound C(CC(=O)O)(=O)O.C[K] CYAXCSFTHFUALI-UHFFFAOYSA-N 0.000 description 1
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- NWZGXBFJMYQUOS-UHFFFAOYSA-N CC(C1)(C(O)=O)C(O)=C(C(C=CC(F)=C2)=C2F)N1C(O)=O Chemical compound CC(C1)(C(O)=O)C(O)=C(C(C=CC(F)=C2)=C2F)N1C(O)=O NWZGXBFJMYQUOS-UHFFFAOYSA-N 0.000 description 1
- KJSWLEWSXPQCMW-UHFFFAOYSA-N CC(N=C1)=CC=C1S(N(C=C1C=O)C(C(C=CC(F)=C2)=C2F)=C1OC)(=O)=O Chemical compound CC(N=C1)=CC=C1S(N(C=C1C=O)C(C(C=CC(F)=C2)=C2F)=C1OC)(=O)=O KJSWLEWSXPQCMW-UHFFFAOYSA-N 0.000 description 1
- JKDWJNOZPWAFMD-UHFFFAOYSA-N CC1=C(C(O)=O)C(OC)=C(C(C=CC(F)=C2)=C2F)N1S(C1=NC(C)=CC=C1)(=O)=O Chemical compound CC1=C(C(O)=O)C(OC)=C(C(C=CC(F)=C2)=C2F)N1S(C1=NC(C)=CC=C1)(=O)=O JKDWJNOZPWAFMD-UHFFFAOYSA-N 0.000 description 1
- GCJWLNPWPZDZCF-UHFFFAOYSA-N CC1=CC=CC(S(N(C=C2C=O)C(C(C=CC(F)=C3)=C3F)=C2OC)(=O)=O)=N1 Chemical compound CC1=CC=CC(S(N(C=C2C=O)C(C(C=CC(F)=C3)=C3F)=C2OC)(=O)=O)=N1 GCJWLNPWPZDZCF-UHFFFAOYSA-N 0.000 description 1
- XHBJAZTVWQKPMO-UHFFFAOYSA-N COC(C(C=O)=C1)=C(C(C=CC=C2)=C2F)N1S(C(C=N1)=CC=C1OC)(=O)=O Chemical compound COC(C(C=O)=C1)=C(C(C=CC=C2)=C2F)N1S(C(C=N1)=CC=C1OC)(=O)=O XHBJAZTVWQKPMO-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 206010017817 Gastric polyps Diseases 0.000 description 1
- 206010017866 Gastritis haemorrhagic Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101100222383 Homo sapiens CXCL13 gene Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000033793 Neuroendocrine tumor of stomach Diseases 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 231100000264 OECD 451 Carcinogenicity Study Toxicity 0.000 description 1
- BUIQRTDBPCHRIR-UHFFFAOYSA-L O[Cr](Cl)(=O)=O Chemical compound O[Cr](Cl)(=O)=O BUIQRTDBPCHRIR-UHFFFAOYSA-L 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- QPFYXYFORQJZEC-FOCLMDBBSA-N Phenazopyridine Chemical compound NC1=NC(N)=CC=C1\N=N\C1=CC=CC=C1 QPFYXYFORQJZEC-FOCLMDBBSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229940127504 Somatostatin Receptor Agonists Drugs 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- KYLSCEJPSBCEDC-UHFFFAOYSA-N [5-(2,4-difluorophenyl)-4-methoxy-1-(6-methylpyridin-2-yl)sulfonylpyrrol-3-yl]methanol Chemical compound CC1=CC=CC(S(N(C=C2CO)C(C(C=CC(F)=C3)=C3F)=C2OC)(=O)=O)=N1 KYLSCEJPSBCEDC-UHFFFAOYSA-N 0.000 description 1
- DSZREXSNXOJERY-UHFFFAOYSA-N [5-(2-fluorophenyl)-4-methoxy-1H-pyrrol-3-yl]methanol Chemical compound COC1=C(C(C=CC=C2)=C2F)NC=C1CO DSZREXSNXOJERY-UHFFFAOYSA-N 0.000 description 1
- XMLJCSFKQSJZLS-UHFFFAOYSA-L [K+].[K+].OC.[O-]C([O-])=O Chemical compound [K+].[K+].OC.[O-]C([O-])=O XMLJCSFKQSJZLS-UHFFFAOYSA-L 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DEXPIBGCLCPUHE-UISHROKMSA-N acetic acid;(4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5, Chemical compound CC(O)=O.C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 DEXPIBGCLCPUHE-UISHROKMSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000013262 cAMP assay Methods 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000011903 deuterated solvents Substances 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- KJOZJSGOIJQCGA-UHFFFAOYSA-N dichloromethane;2,2,2-trifluoroacetic acid Chemical compound ClCCl.OC(=O)C(F)(F)F KJOZJSGOIJQCGA-UHFFFAOYSA-N 0.000 description 1
- DENRZWYUOJLTMF-UHFFFAOYSA-N diethyl sulfate Chemical compound CCOS(=O)(=O)OCC DENRZWYUOJLTMF-UHFFFAOYSA-N 0.000 description 1
- 229940008406 diethyl sulfate Drugs 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003890 endocrine cell Anatomy 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000037902 enteropathy Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 229960004770 esomeprazole Drugs 0.000 description 1
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- QFWPJPIVLCBXFJ-UHFFFAOYSA-N glymidine Chemical compound N1=CC(OCCOC)=CN=C1NS(=O)(=O)C1=CC=CC=C1 QFWPJPIVLCBXFJ-UHFFFAOYSA-N 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960002437 lanreotide Drugs 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 description 1
- 229940107698 malachite green Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- STKQUIFAVSOATK-UHFFFAOYSA-N methyl 5-(2,4-difluorophenyl)-4-methoxy-1-(6-methoxypyridin-3-yl)sulfonylpyrrole-3-carboxylate Chemical compound COC(C(C(OC)=C1C(C=CC(F)=C2)=C2F)=CN1S(C(C=N1)=CC=C1OC)(=O)=O)=O STKQUIFAVSOATK-UHFFFAOYSA-N 0.000 description 1
- ASYOJEPJDJLTED-UHFFFAOYSA-N methyl 5-(2,4-difluorophenyl)-4-methoxy-1-(6-methylpyridin-2-yl)sulfonylpyrrole-3-carboxylate Chemical compound CC1=CC=CC(S(N(C=C2C(OC)=O)C(C(C=CC(F)=C3)=C3F)=C2OC)(=O)=O)=N1 ASYOJEPJDJLTED-UHFFFAOYSA-N 0.000 description 1
- ISAPIVWZMRVPEV-UHFFFAOYSA-N methyl 5-(2-fluorophenyl)-4-methoxy-1-(6-methoxypyridin-3-yl)sulfonylpyrrole-3-carboxylate Chemical compound COC(C(C(OC)=C1C(C=CC=C2)=C2F)=CN1S(C(C=N1)=CC=C1OC)(=O)=O)=O ISAPIVWZMRVPEV-UHFFFAOYSA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 210000000607 neurosecretory system Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 229960001494 octreotide acetate Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- WWTULTKUWBKVGV-UHFFFAOYSA-M potassium;3-methoxy-3-oxopropanoate Chemical compound [K+].COC(=O)CC([O-])=O WWTULTKUWBKVGV-UHFFFAOYSA-M 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- JQJOGAGLBDBMLU-UHFFFAOYSA-N pyridine-2-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=N1 JQJOGAGLBDBMLU-UHFFFAOYSA-N 0.000 description 1
- 229940070891 pyridium Drugs 0.000 description 1
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 description 1
- 229960004157 rabeprazole Drugs 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 239000013643 reference control Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 229940072272 sandostatin Drugs 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 229940078986 somatuline Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000008054 sulfonate salts Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- DQOWWRAXVRAFRT-UHFFFAOYSA-N tert-butyl 2-(2-fluorophenyl)-4-formyl-3-methoxypyrrole-1-carboxylate Chemical compound CC(C)(C)OC(N(C=C1C=O)C(C(C=CC=C2)=C2F)=C1OC)=O DQOWWRAXVRAFRT-UHFFFAOYSA-N 0.000 description 1
- KPKGZDZVQVJESA-UHFFFAOYSA-N tert-butyl N-[[5-(2-fluorophenyl)-4-methoxy-1-pyridin-2-ylsulfonylpyrrol-3-yl]methyl]-N-methylcarbamate Chemical compound CC(C)(C)OC(N(C)CC(C(OC)=C1C(C=CC=C2)=C2F)=CN1S(C1=NC=CC=C1)(=O)=O)=O KPKGZDZVQVJESA-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 208000036506 well differentiated low or intermediate grade gastric neuroendocrine tumor Diseases 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Definitions
- PPIs Proton pump inhibitors
- omeprazole which inhibit gastric acid secretion
- existing PPIs are accompanied by problems in terms of effectiveness and side effects. Specifically, since existing PPIs are unstable under acidic conditions, they are often formulated as enteric agents. in need. In addition, the existing PPI exhibits variation in therapeutic effect due to metabolic enzyme polymorphism and drug interaction with drugs such as diazepam, so improvement is desired.
- PPI is a prodrug activated by gastric acid and acts only on the active proton pump, the maximum drug expression time is delayed, the effect of suppressing acid secretion at night is poor, and it has disadvantages such as having to take it before meals. exist.
- PPI is mainly metabolized through the CYP2C19 enzyme, and there is a large difference in efficacy between individuals due to the genetic polymorphism of the CYP2C19 enzyme.
- a potassium-competitive gastric acid secretion inhibitor (Potassium-Competitive Acid Blocker, P-CAB) is attracting attention.
- Potassium competitive gastric acid secretion inhibitor strongly and rapidly inhibits gastric acid secretion by reversibly and competitively binding with K + ions to proton pump (H + /K + -ATPase), an enzyme involved in the final stage of gastric acid secretion in parietal cells.
- P-CAB formulations show strong inhibition of the normal acidity (pH 1-3) in the stomach compared to the PPI formulations.
- P-CAB preparations are mainly metabolized through the CYP3A4 enzyme, the difference in efficacy between individuals is relatively small, and concerns about interactions with drugs metabolized by the CYP2C19 enzyme are relatively low.
- vonoprazan induces severe hypergastrinemia compared to the existing PPI drug lansoprazole.
- hypergastrinemia can include enterochromaffin-like (ECL)-cell hyperplasia; parietal cell hyperplasia; fundic gland polyp; It can cause problems such as bone loss, damaged bone quality, and fractures.
- ECL enterochromaffin-like
- Verietal cell hyperplasia parietal cell hyperplasia
- fundic gland polyp It can cause problems such as bone loss, damaged bone quality, and fractures.
- vonoprazan is associated with the development of gastric neuroendocrine tumors in carcinogenicity studies in mice and rats.
- discontinuation of administration of P-CAB or PPI-based drugs such as vonoprazan restores excess gastric acid and causes indigestion, so despite the above problems, drug administration cannot be easily stopped.
- NSAIDs nonsteroidal anti-inflammatory drugs
- bonoprazan aggravates the damage to the small intestine caused by various types of NSAIDs.
- NSAID-induced gastrointestinal damage includes edema, erythema, submucosal hemorrhage, erosion, and ulceration. From this point of view, clinically, in the case of vonoprazan, there may be significant limitations in combination with NSAID drugs.
- a local irritant effect occurs due to ion-trap and mitochondrial damage, and systemically due to the decrease in prostaglandin and NO (nitric oxide).
- NO nitric oxide
- damage to vascular endothelial cells causes microcirculation disorders, making the gastrointestinal mucosa very vulnerable to damage and interfering with the mucosal damage recovery mechanism. Due to the combined action of these mechanisms, damage to the mucous membrane of the gastrointestinal tract, ie, gastric ulcer, enteropathy, etc. may occur or be severe.
- H. pylori is known as one of the main causes of gastrointestinal diseases such as chronic gastritis and peptic ulcer and gastric cancer.
- gastrointestinal diseases such as chronic gastritis and peptic ulcer and gastric cancer.
- H. pylori is related to digestive diseases, and the importance of antibacterial treatment agents is increasing day by day.
- antibacterial treatment of Helicobacter pylori reduces the occurrence of bleeding in peptic ulcer.
- patients take clarithromycin and amoxicillin along with gastric acid inhibitors such as PPI as the first-line treatment.
- the bioavailability which is the rate at which the administered drug enters the systemic circulation and is used in the body.
- High bioavailability is one of the essential elements of oral drugs because the higher the bioavailability, the higher the rate and extent to which the active ingredient or part of the drug is absorbed and utilized at the site of action. In general, such bioavailability increases as absorption through the gastrointestinal tract is higher and the degree of first-pass effect is lower. , is affected by the size and shape of the particles, and the surface area of the particles.
- the concentration of the drug in the target organ, in this case the gastric tissue is maintained as well as the bioavailability in the circulatory system. Therefore, drug distribution and maintenance to the target organ, gastric tissue, is judged to be an important pharmacokinetic characteristic in P-CAB drug development.
- somatostatin also known as growth hormone-inhibiting hormone (GHIH)
- GHIH growth hormone-inhibiting hormone
- Gastric acid suppression by taking drugs such as PPI suppresses somatostatin secretion by D cells and promotes gastrin secretion by G cells by a feedback mechanism to induce hypergastrinemia.
- Gastrin promotes epithelial cell growth to induce oxyntic cell hyperplasia in the gastric body and increase parietal cell mass. This leads to proliferation of adenoma cells and hyperplasia of ECL cells, which may increase the risk of neuroendocrine tumors.
- the frequency of neuroendocrine tumors among tumors occurring in the duodenum is relatively high, and it is known that gastrin secretion is the most common form in neuroendocrine tumors occurring in the duodenum, accounting for approximately 65% of the total.
- Somatostatin is a type of neuropeptide that suppresses neurogenic inflammation and regulates the secretion of hormones and neurotransmitters. It is known to inhibit neurogenic inflammation and to be involved in nociception. Somatostatin is known to control the secretion of hormones and neurotransmitters to suppress neuronal inflammation and to be involved in nociception. Inflammatory somatostatin inhibits the proliferation of T lymphocytes and granulocytes in addition to controlling the neuroendocrine system. Somatostatin analogs are known to increase the expression of the anti-inflammatory factor IL-10 and inhibit the expression of the pro-inflammatory factors IFN- ⁇ and TNF- ⁇ .
- IBD inflammatory bowel disease
- the present invention was completed by synthesizing a new compound having excellent inhibitory activity against the proton pump in the present invention.
- the present invention provides a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof.
- the present invention also provides a pharmaceutical composition comprising the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof.
- the present invention also provides a pharmaceutical composition for preventing or treating gastrointestinal ulcer, gastrointestinal inflammatory disease, or gastric acid-related disease, comprising the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof.
- the present invention also provides a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof for use in the prevention or treatment of gastrointestinal ulcers, gastrointestinal inflammatory diseases, or gastric acid-related diseases.
- the present invention also provides a compound represented by Formula 1, or a pharmaceutically acceptable compound thereof, in the manufacture of a medicament for the treatment of a disease or condition for which an acid secretion inhibitor is prescribed, for example, gastrointestinal ulcer, gastrointestinal inflammatory disease, or gastric acid-related disease. Possible uses of salts are provided.
- the present invention also relates to a gastrointestinal ulcer, gastrointestinal inflammatory disease, or gastric acid-related disease comprising administering a therapeutically effective amount of a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof to a subject in need thereof treatment methods are provided.
- the present invention also provides a gastric acid secretion inhibitor comprising the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof.
- the present invention relates to a compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof:
- substituted pyridinyl group is a substituted or unsubstituted pyridinyl group, wherein the substituted pyridinyl group is at least one or more -OH, -O(C 1 -C 4 alkyl), -(C 1 -C 4 alkyl), halogen, or -CN will be replaced with);
- X 1 is halogen, which is F, Cl, Br or I;
- X 2 is hydrogen or halogen which is F, Cl, Br or I;
- R 1 is methyl or ethyl.
- remind can be, for example, substituted or unsubstituted pyridin-3-yl, or substituted or unsubstituted pyridin-2-yl.
- the Is can be, wherein R 2 is —O(C 1 -C 4 alkyl) or —(C 1 -C 4 alkyl).
- the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof according to the present invention may relate to a compound represented by the following Formula 2 or a pharmaceutically acceptable salt thereof:
- X 1 is F
- X 2 is hydrogen or F
- R 1 is methyl or ethyl
- R 2 is —O(C 1 -C 4 alkyl) or —(C 1 -C 4 alkyl).
- -O(C 1 -C 4 alkyl) may be specifically methoxy or ethoxy.
- the -(C 1 -C 4 alkyl) may be specifically methyl or ethyl.
- R 2 may be methoxy, ethoxy, methyl or ethyl. More preferably R 2 may be methoxy or methyl.
- R 1 may be methyl
- R 1 may be methyl
- R 2 may be methoxy or methyl
- X 1 is F
- X 2 is F
- R 1 is methyl
- R 2 may be methoxy or methyl
- X 1 is F; X 2 is hydrogen; R 1 is methyl; and R 2 may be methoxy or methyl.
- X 1 is F
- X 2 is hydrogen or F
- R 1 is methyl
- R 2 may be methoxy
- X 1 is F
- X 2 is hydrogen or F
- R 1 is methyl
- R 2 may be methyl
- Another embodiment of the present invention relates to a compound independently selected from one or any combination of the following: or a pharmaceutically acceptable salt thereof:
- Another more preferred embodiment of the present invention relates to a compound of Formula 2 or a pharmaceutically acceptable salt thereof, and relates to a compound independently selected from one or any combination of the following, or a pharmaceutically acceptable salt thereof. :
- Another more preferred embodiment of the present invention relates to a compound of Formula 2 or a pharmaceutically acceptable salt thereof, and relates to a compound independently selected from one or any combination of the following, or a pharmaceutically acceptable salt thereof.
- a compound of Formula 2 or a pharmaceutically acceptable salt thereof relates to a compound independently selected from one or any combination of the following, or a pharmaceutically acceptable salt thereof.
- the pharmaceutically acceptable salt means a salt commonly used in the pharmaceutical industry, for example, an inorganic ionic salt prepared with calcium, sodium, etc., phosphoric acid, hydrobromic acid, iodic acid, sulfuric acid, etc.
- Organic acid salts prepared from inorganic acid salts, acetic acid, trifluoroacetic acid, citric acid, maleic acid, lactic acid, glycolic acid, ascorbic acid, carbonic acid, vanillic acid, etc., methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, etc.
- amino acid salts prepared from sulfonate salts, glycine, arginine, etc., and amine salts prepared from trimethylamine, triethylamine, etc., but the types of salts implied in the present invention are not limited by these listed salts.
- a pharmaceutical composition comprising a compound of Formula 1 as defined in any of the embodiments described herein, or a pharmaceutically acceptable salt thereof.
- the prevention or treatment of gastrointestinal ulcer, gastrointestinal inflammatory disease or gastric acid-related disease comprising the compound of Formula 1 or a pharmaceutically acceptable salt thereof as defined in any embodiment described in the present invention;
- a therapeutic pharmaceutical composition is provided.
- Gastrointestinal ulcer, gastrointestinal inflammation comprising administering to a subject in need thereof a therapeutically effective amount of a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof as defined in any of the embodiments described in the present invention. a method of treating a disease or a stomach acid-related disease;
- a pharmaceutical composition comprising a compound of Formula 1 as defined in any embodiment described herein, or a pharmaceutically acceptable salt thereof, for treating a disease or condition for which an acid secretion inhibitor is prescribed; or
- a gastric acid secretion inhibitor comprising a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof, as defined in any of the embodiments described in the present invention.
- the above-mentioned compound represented by Formula 1 or a pharmaceutically acceptable salt thereof is preferably a compound represented by Formula 2 or a pharmaceutically acceptable salt thereof.
- the present invention also relates to a compound of formula 1 as defined in any embodiment described herein, or a pharmaceutical thereof, for use in and/or prophylaxis of gastrointestinal ulcers, gastrointestinal inflammatory diseases or gastric acid-related diseases as discussed herein. It relates to a pharmaceutical composition comprising an acceptable salt.
- the gastrointestinal ulcer refers to an ulcer occurring in the digestive system including both the stomach and intestines.
- examples include, but are not limited to, peptic ulcer, gastric ulcer, duodenal ulcer, NSAID induced ulcer, acute stress ulcer, Zollinger-Ellison syndrome, and the like. If the ulcer becomes severe, it can lead to cancer. For example, the gastric ulcer may develop into gastric cancer as the disease severity increases.
- the gastrointestinal ulcer may include damage to the gastric mucosa or damage to the small intestine mucosa caused by drugs or alcohol.
- it may be gastric mucosal damage or small intestinal mucosa induced by NSAIDs or alcohol.
- the gastrointestinal inflammatory disease refers to a disease caused by inflammation of the gastrointestinal tract.
- Helicobacter pylori Helicobacter pylori
- gastritis e.g., acute hemorrhagic gastritis, chronic superficial gastritis, chronic atrophic gastritis
- gastric MALT lymphoma gastric MALT lymphoma, and the like.
- the gastric acid-related disease refers to a disease caused by excessive secretion of gastric acid. Examples include, but are not limited to, erosive esophagitis, non-erosive esophagitis, reflux esophagitis, symptomatic gastroesophageal reflux disease (symptomatic GERD), functional dyspepsia, hyperacidity, upper gastrointestinal bleeding due to invasive stress, etc. does not
- the gastrointestinal ulcer, gastrointestinal inflammatory disease or gastric acid-related disease is peptic ulcer, gastric ulcer, duodenal ulcer, NSAID-induced ulcer, acute stress ulcer, Zollinger-Ellison syndrome, Helicobacter pylori Helicobacter pylori infection, gastritis, erosive esophagitis, non-erosive esophagitis, reflux esophagitis, inflammatory bowel disease, symptomatic gastroesophageal reflux disease (symptomatic GERD), functional dyspepsia, gastric cancer, gastric MALT lymphoma, hyperacidity, And it may be any one or more selected from the group consisting of upper gastrointestinal bleeding due to invasive stress.
- symptomatic GERD symptomatic gastroesophageal reflux disease
- the compound of Formula 2 or a pharmaceutically acceptable salt thereof according to the present invention directly and reversibly inhibits the proton pump, thereby exhibiting a rapid pharmacological effect and low drug interaction, thereby exhibiting an excellent effect in terms of safety in pharmacological terms. .
- the compound of Formula 2 or a pharmaceutically acceptable salt thereof does not inhibit the CYP enzyme, which is a major liver metabolizing enzyme, so it is judged that the possibility of exhibiting drug-drug interaction is low.
- the compound of Formula 2 or a pharmaceutically acceptable salt thereof according to the present invention has a high intragastric distribution and is maintained at a high concentration in the stomach to appropriately control gastric acid activity for a long period of time. It has an advantage in that it exhibits an excellent effect and can have fluidity at the time of administration.
- the compound of Formula 2 or a pharmaceutically acceptable salt thereof according to the present invention exhibits high bioavailability in the oral administration route, thereby exhibiting a very excellent effect in terms of pharmacokinetics. That is, the compound of Formula 2 or a pharmaceutically acceptable salt thereof according to the present invention has excellent bioavailability upon oral administration along with excellent distribution in the stomach.
- the drug concentration in the stomach is maintained at an appropriate level or higher, showing sufficient efficacy, and exhibiting excellent effects without the risk of indigestion, abdominal pain, hypergastrinemia, etc. due to excessive compensatory action.
- the compound of Formula 2 or a pharmaceutically acceptable salt thereof according to the present invention exhibits excellent somatostatin receptor agonist activity. Accordingly, acid secretion can be controlled without the risk of hypergastrinemia by effectively inhibiting gastrin secretion. In addition, the risk of hypergastrinemia is minimized by controlling the concentration of gastrin in the blood. In particular, it shows excellent efficacy in regulating acid secretion without side effects or problems such as hyperplasia and neuroendocrine tumors that may occur due to hypergastrinemia.
- the compound of Formula 2 or a pharmaceutically acceptable salt thereof according to the present invention exhibits inhibitory ability by acting on the proton pump within a short time at low pH, and at the same time reversibly (at an appropriate pH) recovers the enzymatic activity of the proton pump. It shows an excellent effect in terms of showing the action.
- the compound of Formula 2 or a pharmaceutically acceptable salt thereof according to the present invention has excellent therapeutic effect on gastrointestinal damage including gastrointestinal ulcers and gastrointestinal inflammatory diseases caused by causes other than gastric acid through excellent somatostatin receptor agonist activity indicates For example, it can exhibit an excellent effect of improving inflammation and improving gastric mucosa in the gastric mucosa or the small intestine mucosa induced by the drug. Specifically, it can exhibit an excellent effect of improving the mucous membrane of the gastrointestinal tract against NSAID-induced gastrointestinal damage and gastrointestinal inflammatory disease, alcohol-induced gastrointestinal injury and gastrointestinal inflammatory disease. In addition, it can exhibit an excellent effect in disease treatment by remarkably improving the inflammatory cytokine and ROS levels for NSAID-induced gastrointestinal injury and gastrointestinal inflammatory disease, alcohol-induced gastrointestinal injury and gastrointestinal inflammatory disease.
- the compound of Formula 2 or a pharmaceutically acceptable salt thereof according to the present invention exhibits excellent therapeutic efficacy against gastrointestinal ulcers and gastrointestinal inflammatory diseases through excellent somatostatin receptor agonist activity.
- a pharmaceutically acceptable salt thereof according to the present invention exhibits excellent therapeutic efficacy against gastrointestinal ulcers and gastrointestinal inflammatory diseases through excellent somatostatin receptor agonist activity.
- esophagitis or duodenal ulcer by minimizing the ulcer lesion and remarkably improving the inflammatory cytokine and ROS levels, it can exhibit an excellent effect in the treatment of diseases.
- the compound of Formula 2 or a pharmaceutically acceptable salt thereof according to the present invention treats the small intestine damage caused by drugs such as NSAIDs, unlike existing P-CAB drugs, through excellent somatostatin receptor agonist activity without deterioration
- drugs such as NSAIDs
- somatostatin receptor agonist activity without deterioration
- the therapeutic efficacy for intestinal diseases including inflammatory bowel disease (IBD)
- IBD inflammatory bowel disease
- the compound of Formula 2 or a pharmaceutically acceptable salt thereof according to the present invention enhances the antibacterial effect of an antibiotic against Helicobacter pylori (H.pylori ) by reducing gastric acidity, thereby increasing chronic gastritis and peptic ulcer and gastric cancer caused by Helicobacter pylori It is useful for the prevention and treatment of digestive diseases such as
- Boc tert -butoxycarbonyl protecting group
- DIBAL-H diisobutylaluminum hydride
- halogen refers to fluoride, chloride, bromide, or iodide.
- alkyl in the present invention means a straight-chain or branched hydrocarbon group of the formula -C n H (2n+1).
- Non-limiting examples thereof include methyl, ethyl, propyl, isopropyl, butyl, 2-methyl-propyl, 1,1-dimethylethyl, pentyl and hexyl, and the like.
- C 1 -C 4 alkyl may refer to an alkyl such as methyl, ethyl, propyl, butyl, 2-methyl-propyl, and isopropyl.
- alkoxy means “-O-alkyl” or “alkyl-O-”, where alkyl is as defined above.
- the symbol “ " may be a substituted or unsubstituted pyridinyl group.
- the substituted pyridinyl group is as defined above.
- pyridinyl group refers to a 6-membered heteroaryl compound containing 1 nitrogen atom and 5 carbon atoms.
- Non-limiting examples of pyridinyl groups include:
- the -O(C 1 -C 4 alkyl) may be specifically methoxy or ethoxy.
- the -(C 1 -C 4 alkyl) may be specifically methyl or ethyl.
- R 2 is —O(C 1 -C 4 alkyl) or —(C 1 -C 4 alkyl).
- the -O(C 1 -C 4 alkyl) may be specifically methoxy or ethoxy.
- the -(C 1 -C 4 alkyl) may be specifically methyl or ethyl.
- the present invention comprises a pharmaceutical composition.
- the present invention provides a pharmaceutical composition for preventing and treating gastrointestinal ulcer, gastrointestinal inflammatory disease, or gastric acid-related disease, comprising the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof.
- the pharmaceutical composition may include a compound of the present invention together with a pharmaceutically acceptable carrier.
- a pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible.
- composition of the present invention may be in various forms. These include, for example, liquid, semi-solid and solid dosage forms, such as liquid solutions (eg, injectable and infusible solutions), dispersions or suspensions, tablets, pills, powders, liposomes and suppositories.
- liquid solutions eg, injectable and infusible solutions
- dispersions or suspensions tablets, pills, powders, liposomes and suppositories.
- tablets, pills, powders, liposomes and suppositories The form depends on the intended mode of administration and the therapeutic use.
- compositions are in the form of compositions similar to injectable and infusible solutions.
- One mode of administration is parenteral (eg, intravenous, subcutaneous, intraperitoneal, intramuscular).
- Oral administration of solid dosage forms may be presented, for example, as hard or soft capsules, pills, cachets, lozenges or tablets, each containing a predetermined amount of one or more compounds of the present invention.
- oral administration may be in powder or granular form.
- oral administration may be in a liquid dosage form.
- Liquid dosage forms for oral administration include, for example, pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing an inert diluent (eg, water) commonly used in the art.
- parenteral dosage forms in another embodiment, encompasses parenteral dosage forms.
- Parenteral administration includes, for example, subcutaneous injection, intravenous injection, intraperitoneal injection, intramuscular injection, intrasternal injection, and infusion.
- injectable preparations ie, sterile injectable aqueous or oleaginous suspensions
- suitable dispersing, wetting and/or suspending agents may be formulated according to known techniques using suitable dispersing, wetting and/or suspending agents.
- compositions of the present invention may be prepared by any of the well known pharmaceutical techniques, such as effective formulation and administration procedures.
- the compounds of the present invention are administered in an amount effective to treat the conditions described herein.
- a compound of the present invention may be administered as the compound itself or, alternatively, as a pharmaceutically acceptable salt.
- the compound itself, or a pharmaceutically acceptable salt thereof will be referred to simply as a compound of the present invention.
- the compounds of the present invention are administered by any suitable route, in the form of a pharmaceutical composition suitable for such route, and in a dosage effective for the intended treatment.
- the compounds of the present invention may be administered orally, rectally, vaginally, parenterally, or topically.
- the compounds of the present invention may preferably be administered orally.
- Oral administration may involve swallowing the compound to enter the gastrointestinal tract.
- the compounds of the invention may also be administered directly into the bloodstream, into a muscle or an internal organ.
- Suitable means for parenteral administration include intravenous, intraarterial, intraperitoneal, intramuscular and subcutaneous.
- the compound of the present invention and/or a composition containing the compound may be administered according to the type, age, weight, sex, and medical condition of the patient; severity of symptoms; route of administration; and the activity of the particular compound employed. Accordingly, dosing regimens may vary widely.
- the total daily dosage of a compound of the invention is typically from about 0.001 to about 100 mg/kg (i.e., mg of a compound of the invention per kg body weight) for the treatment of a given condition discussed herein. )to be.
- Suitable subjects according to the present invention include mammalian subjects.
- a human is a suitable subject.
- a human subject can be male or female and at any stage of growth.
- the compound of Formula 1 of the present invention includes the compounds of Examples prepared below.
- the compounds of the examples may be prepared or prepared based on various methods described in the literature based on the compounds of the intermediates and common knowledge known to those skilled in the art.
- the compounds of the examples may be prepared or prepared based on the routes of the following Scheme 1 or Scheme 2 described in the literature based on the compounds of the intermediates, or on the basis of common technical knowledge known to those skilled in the art.
- Schemes 1 and 2 to be described below disclose a method for preparing Formula 1 through an intermediate.
- Scheme 3 to be described below discloses a method for preparing the intermediate (I) used in Scheme 1.
- Scheme 4 described below discloses a method for preparing the intermediate (VI) used in Scheme 2.
- Intermediate (II) can be prepared through the reaction shown in step (I) using Intermediate (I) and Intermediate (V) to be described later.
- This reaction is a process for introducing an appropriate heteroarylsulfonyl group using a base in the presence of an inert solvent.
- the solvent used in the reaction of step (I) is preferably toluene, hydrocarbons such as benzene, ethers such as tetrahydrofuran and diethyl ether, N,N -dimethylformamide, or a mixed solvent thereof, but is not limited thereto.
- the base used in this reaction is preferably an inorganic salt such as sodium hydroxide, a basic salt such as cesium carbonate, or a metallic salt such as sodium methoxide, but is not limited thereto.
- the preferred reaction time of this reaction varies depending on the compound, but is generally from 10 minutes to 16 hours.
- the preferred reaction temperature for this reaction varies depending on the compound, but is generally 0°C to 140°C.
- the reaction may be carried out under addition of a crown ether, and examples of the crown ether include 15-crown-5-ether.
- Ring A of the intermediate (V) is as defined in Formula 1 above.
- the symbol “X” of the intermediate (V) means a halogen element, for example, a halogen element such as F, Cl, and Br.
- Step (III) can be prepared from Intermediate (II) through the reaction represented by Step (II).
- the step (II) reaction is a process of reduction using a reducing agent in the presence of an inert solvent.
- the solvent used in this reaction is preferably hydrocarbons such as toluene and benzene, ethers such as tetrahydrofuran and diethyl ether, or a mixed solvent thereof, but is not limited thereto.
- the reducing agent used in this reaction is preferably diisobutylaluminum hydride, lithium aluminumhydride, or the like, but is not limited thereto.
- the preferred reaction time of this reaction varies depending on the compound, but is preferably 10 minutes to 6 hours.
- the preferred reaction temperature of this reaction varies depending on the compound, but is preferably -78°C to 25°C.
- Step (III) reaction is a process of oxidation using an oxidizing agent in the presence of an inert solvent.
- the solvent used in this reaction is preferably an organic halogen solvent such as dichloromethane or a mixed solvent thereof, but is not limited thereto.
- the oxidizing agent used in this reaction is preferably Dess-Martin periodinane, pyridium chlorochromate, or the like, but is not limited thereto.
- the preferred reaction time of this reaction varies depending on the compound, but is preferably 10 minutes to 6 hours.
- the preferred reaction temperature for this reaction varies depending on the compound, but is preferably 0°C to 25°C.
- the compound of formula 1 can be prepared from the intermediate (IV) through the reaction represented by step (IV).
- Step (IV) reaction is a reductive amination process using an appropriate amine and a reducing agent.
- the solvent used in this reaction is preferably, but not limited to, ethers such as tetrahydrofuran and diethyl ether, alcohols such as methanol and ethanol, or a mixed solvent thereof.
- ethers such as tetrahydrofuran and diethyl ether
- alcohols such as methanol and ethanol
- a mixed solvent thereof preferably, but not limited to, ethers such as tetrahydrofuran and diethyl ether, alcohols such as methanol and ethanol, or a mixed solvent thereof.
- an imine is produced through a reaction with a suitable amine, for example, methylamine, etc. for an appropriate time, and a suitable reducing agent is added to complete the reaction.
- the reducing agent used in this reaction is preferably sodium borohydride, sodium cyanoborohydride, or sodium triacetoxyborohydride, but is not limited thereto.
- the preferred reaction time of this reaction varies depending on the compound, but is preferably 1 hour to 6 hours.
- the preferred reaction temperature of this reaction varies depending on the compound, but is preferably 0°C to 60°C.
- Intermediate (VII) can be prepared from Intermediate (VI) according to the same or similar method to the preparation method of step (I) of Scheme 1 above.
- the compound of formula (1) can be prepared from the intermediate (VII) through the reaction represented by step (V).
- Step (V) reaction is a deprotection process that removes the protecting group under suitable conditions.
- the deprotection reaction is not limited to specific acid or base conditions, for example, hydrogen chloride-1,4-dioxane solution, trifluoroacetic acid-dichloromethane, potassium carbonate-methanol solution, etc., but is not limited thereto. .
- the preferred reaction time of this reaction varies depending on the compound, but is preferably 10 minutes to 6 hours.
- the preferred reaction temperature of this reaction varies depending on the compound, but is preferably 0°C to 25°C.
- Step (IX) can be prepared from intermediate (VIII) through the reaction indicated by step (VI).
- Step (VI) reaction is a process for introducing a protecting group to the amine group of intermediate (VIII).
- the protecting group introduction reaction may be carried out according to, for example, well-known methods such as various methods suggested by T.W. Green (Protective Groups in Organic Synthesis, 4th Ed. 2007, Wiely & Sons).
- Step (X) can be prepared from Intermediate (IX) through the reaction represented by Step (VII).
- Step (VII) reaction is a Kleison condensation reaction for synthesizing beta-ketoesters from carboxylic acids. It is a reaction in which activation through an appropriate leaving group, for example, carbonyldiimidazole, etc., followed by condensation via Turbo Grignard, for example, magnesium chloride, etc., followed by decarboxylation at an appropriate acidity, for example, acidic conditions .
- the solvent used in this reaction is preferably ethers such as tetrahydrofuran and diethyl ether, or other mixed solvents, but is not limited thereto. Although this reaction varies depending on the compound, it is preferably from 3 hours to 24 hours at room temperature, but is not limited thereto.
- Step (VIII) reaction is a pyrrole cyclization reaction proceeding under suitable conditions.
- the cyclization is a reaction in which a beta-ketoester substrate generates an activated methylene group in the presence of N,N-dimethylformamide dimethyl acetal, and cyclization proceeds by nucleophilic attack of nitrogen in the molecule.
- the solvent used in this reaction is preferably hydrocarbons such as toluene and benzene, etheths such as 1,4-dioxane, or a mixed solvent thereof, but is not limited thereto.
- the preferred reaction time of this reaction varies depending on the compound, but is preferably 2 hours to 12 hours.
- the preferred reaction temperature of this reaction varies depending on the compound, but is preferably 40°C or higher, and in some cases 100°C or higher.
- Step (IX) reaction is the alkylation of the hydroxyl group of the compound.
- the solvent used in this reaction is preferably, but not limited to, ethers such as tetrahydrofuran and diethyl ether, alcohols such as methanol and ethanol, N,N -dimethylformamide, or a mixed solvent thereof.
- the alkylation may be carried out in the presence of an appropriate base, for example, by reacting with diethyl sulfate, dimethyl sulfate, etc. in potassium carbonate, or by using an alkylating agent such as trimethylsilyl diazomethane.
- the preferred reaction time of this reaction varies depending on the compound, but is preferably 3 hours to 24 hours.
- the preferred reaction temperature of this reaction varies depending on the compound, but is preferably 0°C to 50°C.
- Intermediate (I) can be prepared from Intermediate (XII) according to the same or similar method to the preparation method of step (V) of Scheme 2 above.
- Intermediate (XIII) can be prepared from Intermediate (XII) according to the same or similar method to the preparation method of step (II) of Scheme 1.
- Intermediate (XV) can be prepared from Intermediate (XIV) according to the same or similar method to the preparation of step (V) of Scheme 2.
- Intermediate (VI) can be prepared from Intermediate (XV) according to the same or similar method over two steps of Schemes 1 and 3, Steps (IV) and (VI).
- novel derivative or pharmaceutically acceptable salt thereof of the present invention reversibly inhibits the direct proton pump, thereby exhibiting a rapid pharmacological effect and low drug interaction.
- a high pharmacological effect can be exhibited even with a small dose, and the compound has a high intragastric distribution and is maintained at an appropriate level or higher in the stomach to control gastric acid activity for a long period of time.
- Methyl 4-(( tert -butoxycarbonyl)amino)-4-(2-fluorophenyl)-3-oxobutanoate (1.0 eq., 15.4 g, 47.33 mmol) and N,N -dimethylformamide Dimethyl acetal (3.0 eq., 19 mL, 142.00 mmol) was added to toluene (300 mL) and stirred at 40° C. for 4 hours to complete the reaction. It was evaporated under reduced pressure to remove toluene, and EA and water were added. After neutralization to about pH 7 using 1 N HCl, it was extracted twice with EA.
- 2-amino-2-(2,4-difluorophenyl)acetic acid (1.0 eq., 7.22 g, 38.6 mmol) was dissolved in THF/H 2 O (1:1, 200 mL) and then cooled to 0° C. .
- NaHCO 3 (3.0 eq., 9.74 g, 116 mmol)
- Boc 2 O (1.2 eq., 10.64 mL, 46.3 mmol) was added, and after stirring at room temperature overnight, water was added to the reaction solution to adjust the pH to 2.5. Extracted with EA.
- Boc 2 O (1.2 eq., 2.53 mL, 11.0 mmol) was slowly added thereto and stirred at room temperature for 1 hour.
- the organic layer was dried over anhydrous magnesium sulfate, filtered, concentrated, and purified by silica chromatography, followed by tert -butyl ((5-(2,4-difluorophenyl)-4-methoxy- 1H -pyrrol-3-yl). )methyl)(methyl)carbamate (2.46 g, 76%) was obtained as a brown solid.
- Examples 1 to 6 were synthesized below. Their synthesis method is based on Schemes 1 and 2 above. The preparation methods of Examples 1 to 6 below are specifically described as an example of preparation for the compounds of Examples above.
- Methyl 5- (2-fluorophenyl) -4-methoxy-1 - ((6-methoxypyridin-3-yl) sulfonyl) -1 H-pyrrole-3-carboxylate (1.0 eq, 1.0. g, 2.38 mmol) was dissolved in THF (5.0 mL), DIBAL 1.0 M in n -hexane solution (5.0 eq., 11.9 mL, 11.9 mmol) was added dropwise at 0 °C, followed by stirring at room temperature for 1 hour. The reaction solution was cooled to 0 °C, the reaction was terminated with an aqueous Rochelle salt solution, and extraction was performed with EA.
- Methyl 5-(2,4-difluorophenyl)-4-methoxy-1 H -pyrrole-3-carboxylate (intermediate 3, 1.0 eq., 802 mg, 3.00 mmol) and NaH (1.5 eq., 180 mg, 4.5 mmol) was dissolved in anhydrous DMF (15.0 mL) and stirred at room temperature for 10 minutes.
- 6-Methoxypyridine-3-sulfonyl chloride 1.5 eq., 934 mg, 4.50 mmol was added and stirred at room temperature for 1 hour. After adding distilled water to the reaction solution, it was washed with brine and extracted with EA.
- Methyl 5-(2,4-difluorophenyl)-4-methoxy-1 H -pyrrole-3-carboxylate (intermediate 3, 1.0 eq., 534 mg, 2.0 mmol) and NaH (1.5 eq., 120 mg, 3.0 mmol) was dissolved in anhydrous DMF (10.0 mL) and stirred at 50° C. for 50 minutes.
- 6-methylpyridine-3-sulfonyl chloride 1.5 eq., 575 mg, 3.0 mmol was added, followed by stirring at 50° C. for 16 hours. After adding distilled water to the reaction solution, it was washed with brine and extracted with EA.
- tert -butyl ((5-(2-fluorophenyl)-4-methoxy-1 H -pyrrol-3-yl)methyl)(methyl)carbamate (intermediate 2, 100.0 mg, 0.3 mmol), NaH (24.0 mg, 0.6 mmol) and 15-crown-5-ether (0.9 mL, 0.5 mmol) were dissolved in anhydrous THF (1.5 mL) and stirred at 50° C. for 10 minutes.
- 6-methylpyridine-3-sulfonyl chloride (86.0 mg, 0.5 mmol) was added and stirred at room temperature for 30 minutes. After adding distilled water to the reaction solution, it was washed with brine and extracted with EA.
- Methyl 5-(2,4-difluorophenyl)-4-methoxy-1 H -pyrrole-3-carboxylate (intermediate 3, 1.0 eq., 400.0 mg, 1.5 mmol) and NaH (1.5 eq., 90.0 mg, 2.25 mmol) was dissolved in anhydrous DMF (10.0 mL) and stirred at room temperature for 30 minutes.
- 6-Methyl-pyridine-2-sulfonyl chloride 1.5 eq., 430 mg, 2.25 mmol was added and stirred at room temperature for 5 hours. After adding distilled water to the reaction solution, it was washed with brine and extracted with EA.
- Methyl 5- (2,4-difluorophenyl) -4-methoxy-1 - ((6-methylpyridin-2-yl) sulfonyl) -1 H-pyrrole-3-carboxylate (1.0 eq,. 439.0 mg, 1.04 mmol) was dissolved in anhydrous THF (5.0 mL), and then DIBAL 1.0 M in THF solution (3.0 eq., 3.12 mL, 3.12 mmol) was added dropwise at 0 °C. Then, it was stirred at room temperature for 2 hours. MeOH was added to the reaction solution, washed with an aqueous Rochelle salt solution, and extracted with EA.
- tert -butyl ((5-(2-fluorophenyl)-4-methoxy-1 H -pyrrol-3-yl)methyl)(methyl)carbamate (intermediate 2, 1.0 eq.), NaH (1.5 eq. , 90.0 mg, 2.25 mmol) and 15-crown-5-ether (catalytic amount) were dissolved in anhydrous THF (10.0 mL) and stirred at room temperature for 30 minutes. Pyridine-2-sulfonyl chloride (1.5 eq., 430 mg, 2.25 mmol) was added and stirred at room temperature for 5 hours. After adding distilled water to the reaction solution, it was washed with brine and extracted with EA.
- the compounds listed in Table 1 were synthesized in the same or similar manner as described above, using commercially available appropriate starting materials and intermediates.
- the prepared intermediates and examples were purified using methods well known to those skilled in the art, which are not limited to silica gel chromatography, recrystallization, and the like.
- the final compound obtained from the reaction mixture can be isolated as a neutral, acid or base salt.
- the proton pump (H + /K + -ATPase) inhibitory activity of the prepared compound was measured as follows. Gastrointestinal vesicles isolated from pig stomach are described in Methods Mol Biol . 2016;1377:19-27. The protein content of the gastrointestinal endoplasmic reticulum was quantified with a Bicinchoninic Acid (BCA) kit (Sigma Aldrich, BCA1). Add 70 ⁇ l of 50 mM Tris-HEPES buffer (pH 6.5) containing 125 ng of vesicles, DMSO or each concentration (final DMSO concentration of 1%), 5 mM MgCl 2 and 10 mM KCl to each well of a 96-well plate.
- BCA Bicinchoninic Acid
- %inhibition [1-(OD treatment group -OD KCl control group )/(OD DMSO control group -OD KCl control group ))]*100.
- IC 50 was analyzed for nonlinear regression of the GraphPad Prism7 program using the %inhibition value for each concentration, and the results are shown in Table 2 below.
- the compounds according to the present invention have an excellent effect on inhibiting acid secretion without side effects on hypergastrinemia.
- the agonism effect on SSTR4 was confirmed by cell-based cAMP functional assay. Using CHO cells in which human SSTR4 is stably expressed, test substances were treated by concentration, reacted at 37°C for 30 minutes, and the amount of cAMP produced was measured by the HTRF detection method. % response compared to the reference control agonist (sst-14, 10 nM) was calculated, and EC 50 was calculated through the concentration-response curve, and the results are shown in Table 5 below.
- the compounds according to the present invention exhibited excellent effects as SSTR4 agonists.
- the inhibitory efficacy of the prepared compound on basal gastric acid secretion was measured by applying the Shay's rat model [Shay H, et al., Gastroenterology, 1945, 5, 43-61].
- the example compound was suspended in a 0.5% methylcellulose solution at a dose of 10 mg/10 mL/kg and administered orally.
- the rats were sacrificed under Zoletil and Xylazine anesthesia, the abdominal cavity was incised to remove the gastric contents, and the obtained contents were centrifuged at 3,000 rpm for 10 minutes to separate only the supernatant and gastric juices were collected. 1 mL of the collected gastric juice was taken into a beaker and pH was measured using an electrode pH meter. To 1 mL of gastric juice, 0.03 mL each of 0.5% dimethylaminoazobenzene alcohol solution and 1% phenolphthalein alcohol solution was added to give a red color, and then 0.1N NaOH solution was added to determine the volume until a rose color appeared. The total acid output was obtained by multiplying the acidity of the stomach by the amount of gastric juice. The % inhibitory activity of the Example compound was calculated according to Equation 2 below, and the results are shown in Table 6 below.
- Example compound [(total gastric acid secretion in control group - total gastric acid secretion in group treated with Example compound) / total gastric acid secretion in control group] X 100
- Ghosh &Schild's method [Ghosh MN, et al., Br J Pharmacol Chemother ., 1958, 13(1), 54 ⁇ 61] was applied for the inhibitory efficacy of the prepared compound on histamine-stimulated gastric acid secretion. It was measured in a rat (Lumen perfused rat, LPR) model.
- a silicone tube was intubated between the stomach and esophagus of fasted male Sprague Dawley (SD) rats, and physiological saline was allowed to perfuse at the same time.
- SD Sprague Dawley
- a silicone tube was intubated between the pylorus and the duodenum to allow the perfusate that had passed through the stomach to come out.
- histamine was injected at the same time through a syringe pump to stabilize the pH in the stomach to about 2.5.
- methyl cellulose was administered to the control group through the jugular vein or duodenum, and for the PPI control group, omeprazole, esomeprazole, lansoprazole or rabeprazole was administered.
- the other groups were injected with the example compound by the same route.
- the perfusate was collected by 7.5 mL every 15 minutes after drug administration, and the pH was measured.
- control group was orally administered with a 0.5% methylcellulose solution
- example compound was suspended in a 0.5% methylcellulose solution at a dose of 10 mg/10 mL/kg. Orally administered.
- Indomethacin was orally administered 1 hour after oral administration of the compound of Example, and after 5 hours, the test animals were killed and the stomach was enucleated. After washing the excised surface of the stomach, the large portion of the stomach was incised. After the incised stomach was widely spread and fixed, the area of the damaged area on the gastric mucosa and the total area of the stomach were calculated using ImageJ software (NIH, Bethesda) to determine the ratio of the damaged area. It was calculated according to Equation 3, and the results are shown in Table 7 below.
- % inhibitory activity of Example compound [(Ratio of gastric injury area in control group - Ratio of gastric injury area in group treated with Example compound) / (Ratio of gastric injury area in control group)] X 100
- Alcohol can directly cause damage and bleeding to the gastric mucosa, and indirectly promote the secretion of inflammatory cytokines, lipopolysaccharides, endotoxins, or free radicals through infiltration of macrophages and neutrophils to induce both gastric ulcer and gastrointestinal inflammation. do.
- a model of alcohol-induced gastric injury and in a rat model of gastrointestinal inflammatory disease to evaluate the gastric ulcer inhibitory efficacy and gastrointestinal anti-inflammatory efficacy of the Example compound, the following procedure was performed.
- control group was orally administered with a 0.5% methylcellulose solution
- other groups were orally administered by suspending the Example compound in a 0.5% methylcellulose solution.
- control group was orally administered with a 0.5% methylcellulose solution
- other groups were orally administered by suspending the Example compound in a 0.5% methylcellulose solution.
- the test animal was anesthetized, and then the pyloric region of the stomach and the boundary region between the dislocation of the stomach and the body were further ligated to allow gastric acid to reflux into the esophagus.
- the stomach and esophagus of the test animal were carefully removed, the contents of the stomach were collected, the gastric juice was collected, and the pH of the gastric juice and the amount of gastric juice were measured.
- the extracted esophagus was incised in the longitudinal direction and fixed to expose the mucous membrane. Esophageal injury area was analyzed using ImageJ software (NIH, Bethesda).
- control group was orally administered with 0.5% methylcellulose solution
- other groups were orally administered by suspending the Example compound in 0.5% methylcellulose solution.
- Example compound mepirizole was orally administered, and after a certain period of time, the test animals were sacrificed and the duodenum was removed. After washing the surface of the excised duodenum with physiological saline, the damaged area was analyzed using ImageJ software (NIH, Bethesda).
- Example compound according to the present invention In order to observe changes in gastrin in the blood after administration of the Example compound according to the present invention, it was carried out as follows.
- control group was orally administered with a 0.5% methylcellulose solution
- other groups were orally administered by suspending the Example compound in a 0.5% methylcellulose solution.
- the control group was intraperitoneally administered 0.5% methylcellulose solution, and the other groups were intraperitoneally administered by suspending the Example compound in 0.5% methylcellulose solution every day for a certain period of time. my dose.
- indomethacin was orally administered to induce inflammation of the small intestine.
- test animals were sacrificed and the small intestine was removed. After the surface of the excised small intestine was washed with physiological saline, damage to the small intestine such as bleeding and inflammation was analyzed through histological analysis.
- the extracted small intestine tissue was homogenized, centrifuged, and total RNA was obtained from the small intestine tissue from the supernatant, and the amount of inflammatory cytokine mRNA in the small intestine tissue was measured.
- Example compound was administered to Sprague Dawley rats, the control group was orally administered with 0.5% methylcellulose solution, and the other groups were orally administered daily for 2 years by suspending a high dose of Example compound in 0.5% methylcellulose solution. After a certain period of time, the test animals were killed, the stomach and duodenum were excised and fixed, and then, ECL cell hyperplasia and the development of neuroendocrine tumors were observed by histopathological analysis, and this was compared with the control group.
- the time-wise distribution in the stomach was measured as follows.
- the prepared compound was dissolved in distilled water containing 0.5% methylcellulose to 0.2 mg/mL, and then orally administered at a dosage of 4 mg/kg.
- blood was exsanguinated through the heart and perfused with physiological saline, the gastric tissue was excised and the weight was measured.
- the compound in the gastric tissue was extracted using a homogenizer. After taking the supernatant from the extract and precipitating the protein using acetonitrile, the amount of the Example compound was measured using LC-MS/MS.
- Example 1 showed an excellent intragastric distribution, and the concentration in the stomach at all time points exceeded the in vitro H + /K + ATPase inhibition assay IC 50 .
- AUC last, stomach obtained after a single administration of the compound of Example 1 at a dose of 4 mg/kg
- Acetonitrile containing an internal standard was added to the collected blood sample for protein precipitation.
- the sample extracted through protein precipitation was centrifuged, and then the supernatant was injected into LC-MS/MS to quantitatively analyze the blood concentration of the compound of Example. Based on the blood concentration-time profile obtained as a result, the AUC for each administration route was calculated, and based on this, the bioavailability (F) at the time of oral administration was calculated.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (20)
- 제1항에 있어서,R2는 메톡시, 에톡시, 메틸 또는 에틸인, 화학식 2로 표시되는 화합물 또는 이의 약제학적으로 허용가능한 염.
- 제2항에 있어서,R2는 메톡시 또는 메틸인, 화학식 2로 표시되는 화합물 또는 이의 약제학적으로 허용가능한 염.
- 제1항에 있어서,R1은 메틸인, 화학식 2로 표시되는 화합물 또는 이의 약제학적으로 허용가능한 염.
- 제1항에 있어서,R1은 메틸이며, 및R2는 메톡시 또는 메틸인, 화학식 2로 표시되는 화합물 또는 이의 약제학적으로 허용가능한 염.
- 제1항에 있어서,X1은 F이며;X2는 F이며;R1은 메틸이며; 및R2는 메톡시 또는 메틸인, 화학식 2로 표시되는 화합물 또는 이의 약제학적으로 허용가능한 염.
- 제1항에 있어서,X1은 F이며;X2는 수소이며;R1은 메틸이며; 및R2는 메톡시 또는 메틸인, 화학식 2로 표시되는 화합물 또는 이의 약제학적으로 허용가능한 염.
- 제1항에 있어서,X1은 F이며;X2는 수소 또는 F이며;R1은 메틸이며; 및R2는 메톡시인, 화학식 2로 표시되는 화합물 또는 이의 약제학적으로 허용가능한 염.
- 제1항에 있어서,X1은 F이며;X2는 수소 또는 F이며;R1은 메틸이며; 및R2는 메틸인, 화학식 2로 표시되는 화합물 또는 이의 약제학적으로 허용가능한 염.
- 제1항에 있어서,상기 화학식 2로 표시되는 화합물은 하기 기재된 화합물로 이루어진 군으로부터 선택되는 어느 하나인 화학식 2로 표시되는 화합물 또는 이의 약제학적으로 허용가능한 염:1-(5-(2-플루오로페닐)-4-메톡시-1-((6-메톡시피리딘-3-일)설포닐)-1H-피롤-3-일)-N-메틸메탄아민;1-(5-(2,4-디플루오로페닐)-4-메톡시-1-((6-메톡시피리딘-3-일)설포닐)-1H-피롤-3-일)-N-메틸메탄아민;1-(5-(2,4-디플루오로페닐)-4-메톡시-1-((6-메틸피리딘-3-일)설포닐)-1H-피롤-3-일)-N-메틸메탄아민; 및1-(5-(2-플루오로페닐)-4-메톡시-1-((6-메틸피리딘-3-일)설포닐)-1H-피롤-3-일)-N-메틸메탄아민.
- 제1항 내지 제10항 중 어느 한 항에 따른 화합물 또는 이의 약제학적으로 허용가능한 염을 포함하는 약제학적 조성물.
- 제1항 내지 제10항 중 어느 한 항에 따른 화합물 또는 이의 약제학적으로 허용가능한 염; 및 약학적으로 허용가능한 담체를 포함하는 약제학적 조성물.
- 제1항 내지 제10항 중 어느 한 항에 따른 화합물 또는 이의 약제학적으로 허용가능한 염을 포함하는 위장관 궤양, 위장관 염증질환 또는 위산-관련 질환의 예방 또는 치료용 약제학적 조성물.
- 제13항에 있어서, 위장관 궤양, 위장관 염증질환 또는 위산-관련 질환은 소화 궤양, 위궤양, 십이지장 궤양, NSAID-유도되는 궤양, 급성 스트레스성 궤양, 졸링거-엘리슨 증후군 (Zollinger-Ellison syndrome), 헬리코박터 파일로리(Helicobacter pylori) 감염증, 위염, 미란성 식도염, 비미란성 식도염, 역류 식도염, 염증성 장질환, 증후성 위식도 역류 질환 (증후성 GERD), 기능성 소화불량, 위암, 위 MALT 림프종, 위산 과다증, 및 침습성 스트레스로 인한 상부 위장관 출혈로 이루어진 군으로부터 선택되는 어느 하나 이상인, 위장관 염증질환 또는 위산-관련 질환의 예방 또는 치료용 약제학적 조성물.
- 위장관 궤양, 위장관 염증질환 또는 위산-관련 질환의 치료를 위한 약제의 제조에 있어 제1항 내지 제10항 중 어느 한 항에 따른 화합물 또는 이의 약제학적으로 허용가능한 염의 용도.
- 제15항에 있어서, 위장관 궤양, 위장관 염증질환 또는 위산-관련 질환은 소화 궤양, 위궤양, 십이지장 궤양, NSAID-유도되는 궤양, 급성 스트레스성 궤양, 졸링거-엘리슨 증후군 (Zollinger-Ellison syndrome), 헬리코박터 파일로리(Helicobacter pylori) 감염증, 위염, 미란성 식도염, 비미란성 식도염, 역류 식도염, 염증성 장질환, 증후성 위식도 역류 질환 (증후성 GERD), 기능성 소화불량, 위암, 위 MALT 림프종, 위산 과다증, 및 침습성 스트레스로 인한 상부 위장관 출혈로 이루어진 군으로부터 선택되는 어느 하나 이상인, 용도.
- 치료학적으로 유효한 양의 제1항 내지 제10항 중 어느 한 항에 따른 화합물 또는 이의 약제학적으로 허용가능한 염을 이를 필요로 하는 대상체에게 투여하는 단계를 포함하는 위장관 궤양, 위장관 염증질환 또는 위산-관련 질환의 치료 방법.
- 제17항에 있어서, 위장관 궤양, 위장관 염증질환 또는 위산-관련 질환은 소화 궤양, 위궤양, 십이지장 궤양, NSAID-유도되는 궤양, 급성 스트레스성 궤양, 졸링거-엘리슨 증후군 (Zollinger-Ellison syndrome), 헬리코박터 파일로리(Helicobacter pylori) 감염증, 위염, 미란성 식도염, 비미란성 식도염, 역류 식도염, 염증성 장질환, 증후성 위식도 역류 질환 (증후성 GERD), 기능성 소화불량, 위암, 위 MALT 림프종, 위산 과다증, 및 침습성 스트레스로 인한 상부 위장관 출혈로 이루어진 군으로부터 선택되는 어느 하나 이상인, 방법.
- 위장관 궤양, 위장관 염증질환 또는 위산-관련 질환의 예방 또는 치료에 사용하기 위한 제1항 내지 제10항 중 어느 한 항에 따른 화합물 또는 이의 약제학적으로 허용가능한 염.
- 제19항에 있어서, 위장관 궤양, 위장관 염증질환 또는 위산-관련 질환은 소화 궤양, 위궤양, 십이지장 궤양, NSAID-유도되는 궤양, 급성 스트레스성 궤양, 졸링거-엘리슨 증후군 (Zollinger-Ellison syndrome), 헬리코박터 파일로리(Helicobacter pylori) 감염증, 위염, 미란성 식도염, 비미란성 식도염, 역류 식도염, 염증성 장질환, 증후성 위식도 역류 질환 (증후성 GERD), 기능성 소화불량, 위암, 위 MALT 림프종, 위산 과다증, 및 침습성 스트레스로 인한 상부 위장관 출혈로 이루어진 군으로부터 선택되는 어느 하나 이상인, 화합물 또는 이의 약제학적으로 허용가능한 염.
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022577797A JP7404561B2 (ja) | 2020-06-17 | 2021-06-16 | 新規な酸分泌抑制剤及びその用途 |
US18/011,084 US11767311B2 (en) | 2020-06-17 | 2021-06-16 | Acid secretion inhibitor and use thereof |
CN202180043522.8A CN115884968B (zh) | 2020-06-17 | 2021-06-16 | 新型酸分泌抑制剂及其用途 |
MX2022016515A MX2022016515A (es) | 2020-06-17 | 2021-06-16 | Nuevo inhibidor de la secrecion de acido y uso del mismo. |
AU2021293694A AU2021293694B2 (en) | 2020-06-17 | 2021-06-16 | Novel Acid Secretion Inhibitor and use thereof |
CA3182882A CA3182882A1 (en) | 2020-06-17 | 2021-06-16 | Novel acid secretion inhibitor and use thereof |
EP21826347.3A EP4148050A4 (en) | 2020-06-17 | 2021-06-16 | NOVEL ACID SECRETION INHIBITOR AND USE THEREOF |
PE2022002955A PE20231652A1 (es) | 2020-06-17 | 2021-06-16 | Nuevo inhibidor de la secrecion de acido y uso del mismo |
BR112022025613A BR112022025613A2 (pt) | 2020-06-17 | 2021-06-16 | Novo inibidor de secreção de ácido e uso do mesmo |
DO2022000291A DOP2022000291A (es) | 2020-06-17 | 2022-12-15 | Nuevo inhibidor de la secreción de ácido y uso del mismo |
CONC2023/0000396A CO2023000396A2 (es) | 2020-06-17 | 2023-01-13 | Nuevo inhibidor de la secreción de ácido y uso del mismo |
ECSENADI20232606A ECSP23002606A (es) | 2020-06-17 | 2023-01-16 | Nuevo inhibidor de la secreción de ácido y uso del mismo |
US18/228,672 US20230373954A1 (en) | 2020-06-17 | 2023-08-01 | Novel acid secretion inhibitor and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2020-0073900 | 2020-06-17 | ||
KR20200073900 | 2020-06-17 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/011,084 A-371-Of-International US11767311B2 (en) | 2020-06-17 | 2021-06-16 | Acid secretion inhibitor and use thereof |
US18/228,672 Continuation US20230373954A1 (en) | 2020-06-17 | 2023-08-01 | Novel acid secretion inhibitor and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021256861A1 true WO2021256861A1 (ko) | 2021-12-23 |
Family
ID=79176045
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/007572 WO2021256861A1 (ko) | 2020-06-17 | 2021-06-16 | 신규한 산 분비 억제제 및 이의 용도 |
Country Status (15)
Country | Link |
---|---|
US (2) | US11767311B2 (ko) |
EP (1) | EP4148050A4 (ko) |
JP (1) | JP7404561B2 (ko) |
KR (2) | KR102432523B1 (ko) |
AU (1) | AU2021293694B2 (ko) |
BR (1) | BR112022025613A2 (ko) |
CA (1) | CA3182882A1 (ko) |
CL (1) | CL2022003601A1 (ko) |
CO (1) | CO2023000396A2 (ko) |
DO (1) | DOP2022000291A (ko) |
EC (1) | ECSP23002606A (ko) |
MX (1) | MX2022016515A (ko) |
PE (1) | PE20231652A1 (ko) |
TW (1) | TWI797645B (ko) |
WO (1) | WO2021256861A1 (ko) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114539219A (zh) * | 2022-03-17 | 2022-05-27 | 日照正济药业有限公司 | 一种富马酸伏诺拉生的制备方法 |
WO2023113458A1 (en) * | 2021-12-15 | 2023-06-22 | Ildong Pharmaceutical Co., Ltd. | Novel salt of 1-sulfonyl pyrrole derivative, preparation method thereof and pharmaceutical composition comprising thereof |
WO2023113474A1 (ko) * | 2021-12-15 | 2023-06-22 | 일동제약(주) | 1-설포닐 피롤 유도체의 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물 |
WO2023211843A1 (en) * | 2022-04-25 | 2023-11-02 | Daewoong Pharmaceutical Co., Ltd. | Potassium-competitive acid blockers for the treatment of pathological hypersecretory conditions |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102432523B1 (ko) | 2020-06-17 | 2022-08-16 | 일동제약(주) | 신규한 산 분비 억제제 및 이의 용도 |
KR20230102353A (ko) * | 2021-12-30 | 2023-07-07 | 주식회사 대웅제약 | 삼중음성유방암의 예방 또는 치료용 약학적 조성물 |
TW202411215A (zh) * | 2022-05-23 | 2024-03-16 | 南韓商日東製藥股份有限公司 | 6-甲氧基吡啶-3-基衍生物之製造方法 |
TW202411216A (zh) * | 2022-05-23 | 2024-03-16 | 南韓商日東製藥股份有限公司 | 6-甲氧基吡啶-3-基衍生物之製造方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110288040A1 (en) * | 2006-03-31 | 2011-11-24 | Takeda Pharmaceutical Company Limited | Aryl- or heteroaryl-sulfonyl compounds as acid secretion inhibitors |
US20160009646A1 (en) * | 2013-02-28 | 2016-01-14 | Takeda Pharmaceutical Company Limited | Method for producing sulfonyl chloride compound |
KR20160127646A (ko) * | 2015-04-27 | 2016-11-04 | 주식회사 대웅제약 | 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
KR20170113040A (ko) * | 2016-03-25 | 2017-10-12 | 주식회사 대웅제약 | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 신규한 산부가염 |
WO2019013310A1 (en) | 2017-07-10 | 2019-01-17 | Takeda Pharmaceutical Company Limited | PREPARATION COMPRISING VONOPRAZAN |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8048909B2 (en) * | 2004-09-30 | 2011-11-01 | Takeda Pharmaceutical Company Limited | Proton pump inhibitors |
CN108558831B (zh) * | 2018-06-08 | 2021-07-27 | 上海璃道医药科技有限公司 | 取代吡咯-4-烷基胺类化合物及其用途 |
KR102432523B1 (ko) | 2020-06-17 | 2022-08-16 | 일동제약(주) | 신규한 산 분비 억제제 및 이의 용도 |
-
2021
- 2021-06-16 KR KR1020210078283A patent/KR102432523B1/ko active IP Right Grant
- 2021-06-16 US US18/011,084 patent/US11767311B2/en active Active
- 2021-06-16 WO PCT/KR2021/007572 patent/WO2021256861A1/ko active Application Filing
- 2021-06-16 AU AU2021293694A patent/AU2021293694B2/en active Active
- 2021-06-16 PE PE2022002955A patent/PE20231652A1/es unknown
- 2021-06-16 EP EP21826347.3A patent/EP4148050A4/en active Pending
- 2021-06-16 MX MX2022016515A patent/MX2022016515A/es unknown
- 2021-06-16 KR KR1020210078284A patent/KR20210156235A/ko unknown
- 2021-06-16 BR BR112022025613A patent/BR112022025613A2/pt unknown
- 2021-06-16 CA CA3182882A patent/CA3182882A1/en active Pending
- 2021-06-16 JP JP2022577797A patent/JP7404561B2/ja active Active
- 2021-06-17 TW TW110122142A patent/TWI797645B/zh active
-
2022
- 2022-12-15 CL CL2022003601A patent/CL2022003601A1/es unknown
- 2022-12-15 DO DO2022000291A patent/DOP2022000291A/es unknown
-
2023
- 2023-01-13 CO CONC2023/0000396A patent/CO2023000396A2/es unknown
- 2023-01-16 EC ECSENADI20232606A patent/ECSP23002606A/es unknown
- 2023-08-01 US US18/228,672 patent/US20230373954A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110288040A1 (en) * | 2006-03-31 | 2011-11-24 | Takeda Pharmaceutical Company Limited | Aryl- or heteroaryl-sulfonyl compounds as acid secretion inhibitors |
US20160009646A1 (en) * | 2013-02-28 | 2016-01-14 | Takeda Pharmaceutical Company Limited | Method for producing sulfonyl chloride compound |
KR20160127646A (ko) * | 2015-04-27 | 2016-11-04 | 주식회사 대웅제약 | 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
KR20170113040A (ko) * | 2016-03-25 | 2017-10-12 | 주식회사 대웅제약 | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 신규한 산부가염 |
WO2019013310A1 (en) | 2017-07-10 | 2019-01-17 | Takeda Pharmaceutical Company Limited | PREPARATION COMPRISING VONOPRAZAN |
Non-Patent Citations (5)
Title |
---|
ARIKAWA, Y. ET AL.: "Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3- ylsulfonyl)-l H-pyrrol-3-yl]-Nmethylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB", JOURNAL OF MEDICINAL CHEMISTRY, vol. 55, 2012, pages 4446 - 4456, XP055260738, DOI: 10.1021/jm300318t * |
GHOSH MN ET AL., BR J PHARMACOL CHEMOTHER., vol. 13, no. 1, 1958, pages 54 - 61 |
METHODS MOL BIOL, vol. 1377, 2016, pages 19 - 27 |
See also references of EP4148050A4 |
SHAY H ET AL., GASTROENTEROLOGY, vol. 5, 1945, pages 43 - 611 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023113458A1 (en) * | 2021-12-15 | 2023-06-22 | Ildong Pharmaceutical Co., Ltd. | Novel salt of 1-sulfonyl pyrrole derivative, preparation method thereof and pharmaceutical composition comprising thereof |
WO2023113474A1 (ko) * | 2021-12-15 | 2023-06-22 | 일동제약(주) | 1-설포닐 피롤 유도체의 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물 |
CN114539219A (zh) * | 2022-03-17 | 2022-05-27 | 日照正济药业有限公司 | 一种富马酸伏诺拉生的制备方法 |
WO2023211843A1 (en) * | 2022-04-25 | 2023-11-02 | Daewoong Pharmaceutical Co., Ltd. | Potassium-competitive acid blockers for the treatment of pathological hypersecretory conditions |
Also Published As
Publication number | Publication date |
---|---|
EP4148050A4 (en) | 2023-10-25 |
EP4148050A1 (en) | 2023-03-15 |
CL2022003601A1 (es) | 2023-07-07 |
JP2023524172A (ja) | 2023-06-08 |
TW202214588A (zh) | 2022-04-16 |
MX2022016515A (es) | 2023-01-30 |
CA3182882A1 (en) | 2021-12-23 |
KR20210156234A (ko) | 2021-12-24 |
PE20231652A1 (es) | 2023-10-17 |
TWI797645B (zh) | 2023-04-01 |
KR20210156235A (ko) | 2021-12-24 |
CO2023000396A2 (es) | 2023-02-27 |
BR112022025613A2 (pt) | 2023-01-17 |
DOP2022000291A (es) | 2023-01-15 |
US11767311B2 (en) | 2023-09-26 |
CN115884968A (zh) | 2023-03-31 |
US20230192650A1 (en) | 2023-06-22 |
AU2021293694A1 (en) | 2023-01-19 |
JP7404561B2 (ja) | 2023-12-25 |
ECSP23002606A (es) | 2023-03-31 |
TW202325702A (zh) | 2023-07-01 |
KR102432523B1 (ko) | 2022-08-16 |
US20230373954A1 (en) | 2023-11-23 |
AU2021293694B2 (en) | 2023-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021256861A1 (ko) | 신규한 산 분비 억제제 및 이의 용도 | |
WO2020222461A1 (ko) | 면역항암 보조제 | |
WO2016093554A2 (ko) | 신규한 4-(아릴)-n-(2-알콕시티에노[3,2-b]피라진-3-일)-피페라진-1-카복스아미드 유도체 및 이의 항증식 효과 | |
WO2011122815A2 (en) | Novel quinoxaline derivatives | |
WO2020222541A1 (ko) | 캐스파제 저해제의 프로드럭 | |
WO2012148140A2 (ko) | 혈관 신생 억제 및 항산화 효과를 가지는 이미다졸계 알칼로이드 유도체 및 이의 제조방법 | |
WO2011021864A2 (ko) | 신규한 항암제 보조용 화합물, 이의 제조방법, 이를 포함하는 항암제 보조용 조성물 및 이를 이용한 항암제에 대한 내성을 감소시키는 방법 | |
WO2023080765A1 (ko) | 신규 옥사다이아졸 유도체 및 이의 용도 | |
WO2011014009A2 (ko) | 신규 이치환된 페녹시아세틸계 화합물 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 다약제내성 억제용 약학적 조성물 | |
WO2018169252A1 (ko) | N-벤질-n-페녹시카르보닐-페닐설폰아마이드 유도체 및 그를 포함하는 약제학적 조성물 | |
EP3052484A1 (en) | Sulfonylindole derivatives and method for preparing the same | |
WO2021149900A1 (ko) | 이치환 아다만틸 유도체, 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 포함하는 암 성장 억제용 약학적 조성물 | |
WO2023113474A1 (ko) | 1-설포닐 피롤 유도체의 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물 | |
WO2016108319A1 (ko) | 신규 레바미피드 전구체의 염 및 이의 용도 | |
WO2016144087A1 (ko) | N-페닐-n'-페녹시카르보닐-페닐설폰하이드라자이드 유도체 및 그를 포함하는 약제학적 조성물 | |
EP3867249A1 (en) | Novel (isopropyl-triazolyl)pyridinyl-substituted benzooxazinone or benzothiazinone derivatives and use thereof | |
WO2019098785A1 (ko) | 7-아미노-1h-인돌-5-카르복사미드 유도체 및 이의 용도 | |
WO2023085894A1 (ko) | RORα의 활성자로서의 신규한 티오우레아 유도체 및 이를 포함하는 약학적 조성물 | |
WO2019235894A1 (ko) | Aimp2-dx2와 k-ras의 결합을 저해하는 화합물을 포함하는 고형암 예방 또는 치료용 조성물 및 aimp2-dx2와 k-ras의 결합을 저해하는 신규 화합물 | |
WO2023059121A1 (ko) | 신규한 벤조퓨라닐 히드록시페닐 메타논 유도체 화합물 또는 이의 약학적으로 허용가능한 염 | |
WO2018021762A1 (ko) | 신규 화합물, 이의 제조방법 및 이를 포함하는 약학 조성물 | |
WO2022177307A1 (ko) | 벤즈이미다졸 유도체를 유효 성분으로 포함하는 인터페론 유전자 자극제 조성물 | |
WO2021040349A1 (ko) | 신규 헵신 저해제 및 이를 유효성분으로 포함하는 전이성 암 예방 또는 치료용 약학적 조성물 | |
WO2021080346A1 (ko) | 단백질 키나아제 저해 활성을 갖는 신규한 피리디닐트리아진 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물 | |
WO2021145641A1 (ko) | 혈관생성 저해 효과를 가지는 n-페닐벤조티아졸-2-아민 화합물 및 그를 포함하는 약제학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21826347 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3182882 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022577797 Country of ref document: JP Kind code of ref document: A Ref document number: 2021826347 Country of ref document: EP Effective date: 20221209 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022025613 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112022025613 Country of ref document: BR Kind code of ref document: A2 Effective date: 20221214 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021293694 Country of ref document: AU Date of ref document: 20210616 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 522441734 Country of ref document: SA |